Compugen Limited - נכסים נקיים למניה בודדת CGEN

The price action history of Compugen Ltd. (CGEN) demonstrates the current 0.94 metric. The business relies on the growing interest of pharma behemoths in licensing new antibodies. Compugen Ltd. (CGEN) attracts top bioinformaticians through powerful software and generous stock options. Meanwhile, the operating model is based on the full outsourcing of production and testing, which spares the firm from unnecessary capital expenditures.

The competitiveness of Compugen Ltd. (CGEN) is based on the AI platform's ability to create promising anti-tumor molecules while maintaining sufficient liquidity. An analysis of the average book value per share demonstrates the residual value of net assets minus liabilities per security, allowing investors to assess the actual physical capital backing while awaiting payments from pharmaceutical partners and confirming the long-term sustainability of the business.